Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Go back to Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma| (NASDAQ: GMAB) | Delayed: 34.69 -0.05 (0.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $34.74 | 52 Week High | $ | |||
| Open | $34.70 | 52 Week Low | $ | |||
| Day High | $34.87 | P/E | N/A | |||
| Day Low | $34.36 | EPS | $ | |||
| Volume | 1,577,456 | |||||
